Group 1 - The core point of the news is that Yuan Da Pharmaceutical Group has successfully completed the Phase II clinical trial of its innovative traditional Chinese medicine GPN01360 for treating depression, marking significant progress in the company's product development in the otolaryngology sector [1][2]. - The Chinese depression medication market is projected to grow from approximately 9.7 billion yuan in 2024 to 14.3 billion yuan by 2029, with a compound annual growth rate of 8.1% [1]. - GPN01360 is a Class 1.1 innovative traditional Chinese medicine based on the classic formula "Xiao Yao San," consisting of 12 herbal ingredients, aimed at alleviating symptoms of depression [1]. Group 2 - Positive clinical trial data for GPN01360 lays a foundation for further research and aims to address the issue of poor patient compliance associated with side effects of existing Western medications, potentially improving long-term treatment effectiveness [2]. - The Chinese government has introduced multiple policies to encourage the innovation and development of traditional Chinese medicine, including a directive from the State Council to enhance support for traditional medicine research and innovation [2][3]. - Yuan Da Pharmaceutical is strategically expanding its traditional Chinese medicine offerings beyond otolaryngology to include chronic disease treatment areas such as cardiovascular and neurological conditions, reflecting a shift towards a comprehensive chronic disease treatment strategy [3].
远大医药中药1类创新药GPN01360国内Ⅱ期临床达到终点 剑指百亿元市场